News Sentiment

UNCY sentiment intelligence

Unicycive Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 44 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.21 Week of 10 Jul 2026
Weighted tone 44/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

-9.1% over one week, -28.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -9.1% Price reacting lower
Trend fit Trend inactive -28.1% over four weeks
Fair value -24.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 34
Negative 17

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 8
GlobeNewswire 6
simplywall.st 5
TradingView 4
Finviz 3
Stocktwits 2
Reuters 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 17
Regulatory and legal 6
Analyst action 2
Balance sheet 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
The Globe and Mail Direct company coverage

Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group

Maxim Group analyst Jason McCarthy reiterated a Buy rating for Unicycive Therapeutics (UNCY) with a $30.00 price target, despite the company's recent quarterly GAAP net loss of $12.82 million. The Street maintains a Strong Buy consensus with an average price target of $36.71. Ben

Tone
Positive 70/100
Event
Analyst action
Published
15 Jul 2026 08:42
Source
The Globe and Mail
Stocktwits Direct company coverage

UNCY Retail Buzz Explodes 150% This Week as Traders Bet Big on Experimental Drug Approval

Shares of Unicycive Therapeutics Inc (UNCY) jumped 9% as retail investors speculated on the potential FDA approval of its drug, Oxylanthanum carbonate (OLC). The company resubmitted its application for OLC, a treatment for hyperphosphatemia in chronic kidney disease patients on d

Tone
Positive 75/100
Event
Regulatory and legal
Published
14 Jul 2026 14:42
Source
Stocktwits
GlobeNewswire Direct company coverage

UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation

Block & Leviton is investigating Unicycive Therapeutics, Inc. (UNCY) for potential securities law violations after the FDA issued a second Complete Response Letter for its OLC New Drug Application due to third-party manufacturing deficiencies. Investors who have lost money in Uni

Tone
Negative 25/100
Event
Regulatory and legal
Published
13 Jul 2026 17:39
Source
GlobeNewswire
GlobeNewswire Direct company coverage

UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.

Kirby McInerney LLP is investigating Unicycive Therapeutics, Inc. regarding potential violations of federal securities laws after the FDA issued a second Complete Response Letter for the company's kidney disease therapy, causing a significant stock price drop. Investors who purch

Tone
Negative 25/100
Event
Market update
Published
10 Jul 2026 23:41
Source
GlobeNewswire
Simply Wall Street Direct company coverage

Unicycive Therapeutics (Nasdaq:UNCY) - Stock Analysis

Unicycive Therapeutics (Nasdaq:UNCY) is a clinical-stage biotechnology company focused on kidney disease therapies. The company has recently faced setbacks with its oxylanthanum carbonate drug application due to manufacturing deficiencies, leading to significant stock price drops

Tone
Negative 38/100
Event
Market update
Published
09 Jul 2026 22:41
Source
Simply Wall Street
Stock Titan Direct company coverage

Millennium-affiliated holders disclose 271,456 shares in Unicycive Therapeutics (UNCY)

A Schedule 13G/A filing reveals that Millennium-affiliated entities, including Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, beneficially own 271,456 shares (1.0%) of Unicycive Therapeutics (UNCY). Separately, Integrated Core Strategies (US)

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 22:11
Source
Stock Titan
The AI Journal Direct company coverage

Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announced an investigation into Unicycive Therapeutics, Inc. (UNCY) for possible federal securities law violations. This follows a significant stock price drop after Unicycive disclosed a second Complete Response Letter from the FDA for its kidney

Tone
Negative 27/100
Event
Regulatory and legal
Published
07 Jul 2026 22:44
Source
The AI Journal
TradingView Direct company coverage

Price to book forward of Unicycive Therapeutics, Inc. – NASDAQ:UNCY

The article focuses on the "Price to book forward" metric for Unicycive Therapeutics, Inc. (NASDAQ: UNCY). It appears to be a financial data snippet from TradingView, indicating a specific financial ratio without providing extensive details or analysis. The content primarily list

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 08:41
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Unicycive Therapeutics, Inc. – NASDAQ:UNCY

The article discusses the forward price-to-earnings ratio for Unicycive Therapeutics, Inc. (NASDAQ: UNCY). It provides financial data and links to various tools and resources available on the TradingView platform for analyzing the stock.

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 04:40
Source
TradingView
Finviz Direct company coverage

UNCY - Unicycive Therapeutics Inc Latest SEC Filings

This article provides the latest SEC filing information for Unicycive Therapeutics Inc (UNCY) from Finviz. It includes a comprehensive overview of the company's financial data, stock performance metrics, insider ownership, institutional ownership, and analyst ratings. Key financi

Tone
Neutral 50/100
Event
Analyst action
Published
04 Jul 2026 21:41
Source
Finviz
Finviz Direct company coverage

UNCY - Unicycive Therapeutics Inc Forecast, Target Price

This article provides a detailed financial overview and forecast for Unicycive Therapeutics Inc (UNCY). It includes key financial metrics such as market capitalization, income, sales, EPS, and various ratios, alongside performance indicators like 52-week high/low, volatility, and

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 20:41
Source
Finviz
Finviz Direct company coverage

UNCY - Unicycive Therapeutics Inc Short Interest

This article provides a detailed financial overview of Unicycive Therapeutics Inc (UNCY), focusing on its short interest. It covers key financial metrics, stock performance data, insider and institutional ownership, and various ratios, painting a comprehensive picture of the comp

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 03:39
Source
Finviz
Carroll County Mirror-Democrat Direct company coverage

Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Unicycive Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of its stockholders after the company announced a second Complete Response Letter from the FDA for its New Drug Application. This news led to a nearly 39% decline in Unicycive's sha

Tone
Negative 20/100
Event
Market update
Published
02 Jul 2026 17:40
Source
Carroll County Mirror-Democrat
TradingView Direct company coverage

Unicycive Therapeutics reports $61.4M cash balance as of June 30, 2026

Unicycive Therapeutics reported a preliminary cash balance of approximately $61.4 million as of June 30, 2026, indicating available liquidity. These stated results are preliminary, prepared by management, and have not been audited or reviewed by independent accountants. The compa

Tone
Positive 64/100
Event
Balance sheet
Published
02 Jul 2026 14:40
Source
TradingView
Stock Titan Direct company coverage

Unicycive Therapeutics (UNCY) discloses $61.4M cash balance in preliminary Q2 2026 update

Unicycive Therapeutics, Inc. reported a preliminary, unaudited cash balance of approximately $61.4 million as of June 30, 2026, as part of its second-quarter results. The company disclosed this information via an 8-K filing under Item 8.01, indicating a material event deemed impo

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 14:40
Source
Stock Titan
Market source Direct company coverage

Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies

Unicycive Therapeutics (UNCY) shares dropped 33.1% after the FDA issued a Complete Response Letter for its oxylanthanum carbonate NDA, citing third-party manufacturing deficiencies. The letter raised no concerns about clinical efficacy or safety, but instead highlighted unresolve

Tone
Negative 19/100
Event
Market update
Published
02 Jul 2026 04:13
Source
Market source
Business Wire Direct company coverage

UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Kirby McInerney LLP is investigating potential securities fraud claims against Unicycive Therapeutics, Inc. (NASDAQ: UNCY). This investigation follows a significant 39% stock price drop after Unicycive announced a second Complete Response Letter from the FDA regarding its kidney

Tone
Negative 28/100
Event
Regulatory and legal
Published
01 Jul 2026 22:39
Source
Business Wire
Stock Titan Direct company coverage

[144] Unicycive Therapeutics, Inc. SEC Filing

This article reports on Unicycive Therapeutics, Inc.'s SEC Form 144 filing, which indicates a proposed sale of securities. The filing details the filer information, issuer information, securities to be sold including details of acquisition and payment, and confirms no securities

Tone
Neutral 50/100
Event
Deals and strategy
Published
01 Jul 2026 21:39
Source
Stock Titan
GlobeNewswire Direct company coverage

UNCY ALERT: Unicycive Therapeutics, Inc. Investigated for

Block & Leviton is investigating Unicycive Therapeutics, Inc. (UNCY) for potential securities law violations after the FDA issued a second Complete Response Letter for its OLC New Drug Application, citing unresolved third-party manufacturing deficiencies. This news led to a decli

Tone
Negative 25/100
Event
Market update
Published
01 Jul 2026 15:10
Source
GlobeNewswire
Sahm Direct company coverage

Why Is Unicycive Therapeutics Stock Falling Tuesday?

Unicycive Therapeutics' stock fell over 46% after the FDA issued a Complete Response Letter (CRL) for its kidney disease drug application, citing third-party manufacturing deficiencies. This is the second time the FDA has raised these concerns, despite the company's belief that t

Tone
Negative 20/100
Event
Market update
Published
01 Jul 2026 13:39
Source
Sahm
Reuters Direct company coverage

Unicycive Therapeutics Inc

Unicycive Therapeutics announced that the U.S. FDA has declined to approve its kidney disease drug for elevated phosphate levels in chronic kidney disease patients on dialysis. The FDA cited deficiencies at a third-party manufacturing facility as the reason for the non-approval.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 08:40
Source
Reuters
EIN Presswire Direct company coverage

Unicycive Therapeutics Receives FDA Complete Response Letter for Oxylanthanum Carbonate NDA

Unicycive Therapeutics announced it received a Complete Response Letter (CRL) from the FDA for its oxylanthanum carbonate (OLC) NDA, citing deficiencies at a third-party manufacturing vendor, not related to clinical efficacy or safety. The company is actively discussing labeling

Tone
Negative 40/100
Event
Market update
Published
01 Jul 2026 04:17
Source
EIN Presswire
Stocktwits Direct company coverage

UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval

Unicycive Therapeutics (UNCY) experienced its worst day in over a year after the FDA again refused to approve its drug oxylanthanum carbonate due to third-party manufacturing issues. Despite the setback and potential 5-12 month delay, B. Riley and H.C. Wainwright maintained their

Tone
Negative 33/100
Event
Regulatory and legal
Published
30 Jun 2026 17:34
Source
Stocktwits
GlobeNewswire Direct company coverage

Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors

Johnson Fistel, PLLP is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) following a decline in its stock price. This investigation comes after the FDA issued a second Complete Response Letter for Unicycive's OLC NDA due to unresolved third-party manufacturing deficienci

Tone
Negative 13/100
Event
Regulatory and legal
Published
30 Jun 2026 16:41
Source
GlobeNewswire
grafa.com Direct company coverage

Unicycive gets FDA CRL for OLC kidney drug application

Unicycive Therapeutics (NASDAQ:UNCY) received a Complete Response Letter (CRL) from the FDA for its oxylanthanum carbonate New Drug Application. The CRL cited third-party manufacturing deficiencies as the reason, with no issues raised regarding the drug's safety or efficacy. The

Tone
Negative 19/100
Event
Market update
Published
30 Jun 2026 14:41
Source
grafa.com
StocksToTrade Direct company coverage

UNCY Extends ATM Offering As Dilution Fears Hit The Chart

Unicycive Therapeutics Inc. (NASDAQ: UNCY) shares have fallen by 46.04% due to investor concerns over clinical and financing uncertainties. The company filed a $150 million mixed securities shelf and expanded its at-the-market (ATM) equity program with Guggenheim Securities from

Tone
Negative 18/100
Event
Market update
Published
30 Jun 2026 13:41
Source
StocksToTrade